Sai Parenterals Limited, in its recent Board Meeting held on May 23, 2026, approved and announced its audited financial results for the quarter and year ended March 31, 2026. As the notice is regarding the ‘Outcome of Board Meeting’ and announces the financial results for the quarter and year ended March 31, 2026, the company reported its financial performance with an unmodified opinion from its statutory auditors.

Sai Parenterals Limited, established in 2001, is a Hyderabad-based, diversified pharmaceutical formulations company. The company is engaged in research, development, and manufacturing of products across both domestic and international markets, operating primarily in the branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) segments. Its product portfolio spans therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, and dermatology, with offerings in various dosage forms like injectables, tablets, and capsules. The company operates five manufacturing facilities in India and has recently expanded its global footprint through the acquisition of a controlling stake in Noumed Pharmaceuticals in 2025.